Thelansis

  Neuroblastoma stands as the most prevalent cancer in children below the age of one and constitutes the primary solid tumor found outside the central nervous system across all age brackets. Its clinical behavior encompasses a wide range, delineated into three risk groups: low, medium, and high. Approximately 50% of neuroblastoma cases fall into the high-risk category, determined by age, disease extent, histological findings, and cytogenetic characteristics such as MYCN amplification and DNA ploidy. Notably, children over 18 months with metastatic disease are classified as high-risk due to historically poor outcomes in this subgroup. MYCN amplification also places patients in the high-risk category, except those with L1 MYCN amplified disease undergoing complete resection. The management of high-risk neuroblastoma poses significant challenges and necessitates a comprehensive approach involving multiple modalities. The treatment protocol encompasses chemotherapy, surgical resectio...